The first and only fourth generation recombinant Factor VIII (FVIII) produced in a human cell line without any chemical modification or protein fusion is now available to U.S. Hemophilia A patients. Yankee PR client Octapharma USA has launched two community support programs designed to facilitate access to this innovative therapy. Read all the details at Bloomberg Business.